Description: This OV9A2 monoclonal antibody reacts with human CD59, which is also known as Protectin. This GPI-linked membrane glycoprotein shares structural homology with the murine Ly-6 superfamily. CD59 is expressed on all human lymphocytes, monocytes, granulocytes, and erythrocytes. This protein is also expressed on non-hematopoietic cells, including endothelial cells and neurons. By binding the complement components C8 and C9, CD59 inhibits assembly of the membrane attack complex and cytolytic activity by complement. CD59 interacts with CD2 to modulate T cell adhesion, and also plays a role in T cell activation. Finally, altered expression of CD55 and CD59 on human peripheral blood cells has been observed in patients with systemic lupus erythematosus (SLE).
Crossblocking studies indicate that the OV9A2 monoclonal antibody binds the same epitope as MEM-43.
Applications Reported: This OV9A2 antibody has been reported for use in flow cytometric analysis.
Applications Tested: This OV9A2 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.
Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome.
When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information.
Excitation: 405 nm; Emission: 436 nm; Laser: Violet Laser
Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company.
CD59 (Protectin) is a small (18-20 kDa) GPI-anchored ubiquitously expressed inhibitor of the membrane attack complex (MAC). CD59 is the key regulator that preserves the autologous cells from terminal effector mechanism of the complement cascade. CD59 also associates with C5b-8 complex and counteracts appropriate formation of cytolytic pore within the plasma membrane. Further, CD59 is a low-affinity ligand of human CD2, causes T cell costimulation, and is involved in lymphocyte signal transduction. CD59 is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. Mutations in this gene cause CD59 deficiency, a disease involving hemolytic anemia, thrombosis, and cerebral infarction. Multiple alternatively spliced transcript variants of CD59 have been identified.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 1F5 antigen; 20 kDa homologous restriction factor; CD59; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 glycoprotein; CD59 molecule, complement regulatory protein; HRF-20; human leukocyte antigen MIC11; Ly-6-like protein; lymphocytic antigen CD59/MEM43; MAC-inhibitory protein; MAC-IP; MACIF; MEM43 antigen; membrane attack complex (MAC) inhibition factor; Membrane attack complex inhibition factor; Membrane inhibitor of reactive lysis; MIRL; Protectin; surface anitgen recognized by monoclonal antibody 16.3A5; T cell-activating protein
Gene Aliases: 16.3A5; 1F5; CD59; EJ16; EJ30; EL32; G344; HRF-20; HRF20; MAC-IP; MACIF; MEM43; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20
UniProt ID: (Human) P13987
Entrez Gene ID: (Human) 966